Nucala (Mepolizumab)
Anti-IL-5 monoclonal antibody for severe eosinophilic conditions
Nucala (mepolizumab) is a biologic medicine that targets interleukin-5 (IL-5) to reduce eosinophil levels in the body. It is approved for the treatment of severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype, and hypereosinophilic syndrome (HES). Administered as a subcutaneous injection every 4 weeks, Nucala has been shown to significantly reduce exacerbations and decrease the need for oral corticosteroids.
Quick Facts: Nucala
Key Takeaways
- Nucala is a biologic that blocks IL-5, reducing eosinophil production and alleviating eosinophil-driven inflammation in asthma, EGPA, CRSwNP, COPD, and HES.
- For severe eosinophilic asthma and COPD, the standard adult dose is 100 mg subcutaneously every 4 weeks; for EGPA and HES, the dose is 300 mg (3 injections) every 4 weeks.
- Clinical trials (DREAM, MENSA, SIRIUS) demonstrated a 50% or greater reduction in asthma exacerbations and significant oral corticosteroid sparing.
- The most common side effect is headache; serious allergic reactions including anaphylaxis are rare but possible.
- Nucala does not replace existing controller medications – it is an add-on treatment. Never abruptly stop corticosteroids when starting Nucala.
What Is Nucala and What Is It Used For?
Quick Answer: Nucala (mepolizumab) is a humanized monoclonal antibody that blocks interleukin-5, a protein responsible for the production and survival of eosinophils. It is used to treat several eosinophil-driven diseases including severe asthma, EGPA, CRSwNP, eosinophilic COPD, and HES.
Nucala contains the active substance mepolizumab, a type of protein known as a monoclonal antibody that has been engineered to recognize a specific target substance in the body. Mepolizumab works by binding to and blocking interleukin-5 (IL-5), the key cytokine responsible for the growth, differentiation, recruitment, activation, and survival of eosinophils – a type of white blood cell that plays a central role in allergic and inflammatory responses. By inhibiting IL-5 signaling, Nucala limits the production of eosinophils in the bone marrow and reduces their numbers in the blood and tissues.
Eosinophils are normally part of the immune system and help fight parasitic infections, but when they accumulate in excessive numbers, they can cause chronic inflammation and tissue damage. This eosinophilic inflammation is the underlying mechanism in several diseases that Nucala is designed to treat. The reduction of eosinophils with mepolizumab has been validated in multiple large-scale randomized controlled trials, establishing it as a cornerstone biologic therapy in the management of eosinophilic diseases.
Severe Eosinophilic Asthma
Some people with severe asthma have abnormally high levels of eosinophils in their blood and lungs. This subtype, called eosinophilic asthma, is characterized by persistent airway inflammation despite treatment with high-dose inhaled corticosteroids and long-acting bronchodilators. Nucala is approved as an add-on maintenance treatment for adults, adolescents, and children aged 6 years and older with severe eosinophilic asthma that remains inadequately controlled with standard therapy.
In landmark clinical trials such as DREAM, MENSA, and SIRIUS, mepolizumab demonstrated a significant reduction in the rate of clinically significant asthma exacerbations – by approximately 50% or more – compared to placebo. The SIRIUS trial specifically showed that patients could reduce their oral corticosteroid dose by a median of 50%, with many achieving complete discontinuation of oral steroids while maintaining asthma control. These benefits make Nucala a valuable option for patients who suffer frequent exacerbations despite optimized standard treatment.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Chronic rhinosinusitis with nasal polyps is a condition driven by excessive eosinophilic inflammation in the nasal and sinus mucosa. It causes persistent nasal congestion, loss of smell, and the growth of soft tissue polyps inside the nasal passages. These polyps can significantly impair quality of life and often recur after surgical removal.
Nucala is approved for adults with CRSwNP as an add-on therapy when intranasal corticosteroids provide inadequate control. Clinical studies have demonstrated that mepolizumab reduces nasal polyp size, improves nasal obstruction symptoms, and decreases the need for both sinonasal surgery and oral corticosteroid courses. The treatment addresses the underlying eosinophilic inflammation rather than merely managing symptoms.
Chronic Obstructive Pulmonary Disease (COPD)
A subset of patients with COPD has elevated eosinophil levels in their blood and airways, leading to an eosinophilic inflammatory phenotype. This type of COPD is associated with more frequent exacerbations – episodes of worsening symptoms including increased breathlessness, cough, chest discomfort, and sputum production. COPD is a progressive, long-term disease that gradually worsens over time.
Nucala is approved for adults with an eosinophilic phenotype of COPD as add-on treatment to reduce exacerbation frequency. The METREX and METREO clinical trials showed that mepolizumab reduced the annual rate of moderate-to-severe COPD exacerbations in patients with higher baseline blood eosinophil counts, providing a targeted treatment option for this specific patient population.
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
EGPA, formerly known as Churg-Strauss syndrome, is a rare systemic vasculitis characterized by eosinophilic tissue infiltration and inflammation of small- and medium-sized blood vessels. The disease primarily affects the lungs and sinuses but often involves other organs including the skin, heart, and kidneys. EGPA can cause severe organ damage if left untreated.
Nucala is approved for adults and adolescents aged 6 years and older with relapsing or refractory EGPA. Clinical evidence has shown that mepolizumab significantly increases the proportion of patients achieving remission, extends time to relapse, and enables meaningful reduction of oral corticosteroid doses. The treatment addresses the core eosinophilic pathology of EGPA rather than relying solely on broad immunosuppression.
Hypereosinophilic Syndrome (HES)
Hypereosinophilic syndrome is characterized by persistently elevated blood eosinophil counts that can cause damage to multiple organs, particularly the heart, lungs, nervous system, and skin. The excess eosinophils infiltrate tissues and release toxic granule proteins, leading to inflammation and fibrosis.
Nucala is approved for adults with HES lasting 6 months or more without an identifiable non-hematologic secondary cause. Clinical trials demonstrated that mepolizumab significantly reduced the proportion of HES flares compared to placebo and enabled reduction of concomitant oral corticosteroid therapy, providing better disease control while minimizing the long-term adverse effects of chronic corticosteroid use.
What Should You Know Before Taking Nucala?
Quick Answer: Do not use Nucala if you are allergic to mepolizumab or any of its ingredients. Inform your doctor about any parasitic infections, pregnancy, or planned pregnancy. Never abruptly stop your existing asthma or COPD medications when starting Nucala.
Contraindications
Nucala must not be used if you have a known allergy (hypersensitivity) to mepolizumab or to any of the other ingredients in the formulation, including sucrose, dibasic sodium phosphate heptahydrate, citric acid monohydrate, polysorbate 80, disodium edetate, and water for injections. If you have previously experienced an allergic reaction to mepolizumab or a similar biologic medicine, inform your healthcare provider before starting treatment.
Warnings and Precautions
Worsening asthma or COPD: Some patients may experience asthma-related or COPD-related adverse events, or their condition may worsen during treatment with Nucala. Contact your healthcare provider if you feel your asthma or COPD is not adequately controlled or is getting worse after starting Nucala. Nucala should not be used to treat acute asthma exacerbations or acute bronchospasm.
Allergic and injection site reactions: As with all monoclonal antibodies, Nucala can cause allergic reactions when injected, ranging from mild injection site reactions (pain, redness, swelling) to serious systemic allergic reactions including anaphylaxis. These reactions can occur within minutes to hours after injection, and in some cases symptoms may appear several days later. If you have a history of allergic reactions to any injection or medication, tell your doctor before receiving Nucala.
Parasitic infections: Eosinophils play a role in the immune response against certain parasitic infections. Nucala may weaken your body's ability to fight parasites by reducing eosinophil levels. If you already have a parasitic infection, it should be treated and resolved before starting Nucala therapy. If you live in or travel to regions where parasitic infections are common, discuss this with your healthcare provider.
Herpes zoster risk: Herpes zoster (shingles) infections have been reported in patients receiving Nucala. While the exact mechanism is not fully understood, the immune modulation caused by IL-5 blockade may theoretically contribute to viral reactivation in some patients. Report any new rashes or blisters to your healthcare provider.
Do not abruptly discontinue oral corticosteroids when starting Nucala. Corticosteroid dose reductions must be gradual and supervised by your physician. Sudden withdrawal of corticosteroids can cause adrenal crisis and disease flare.
Use in Children and Adolescents
For severe eosinophilic asthma, Nucala is approved for children aged 6 years and older. Children aged 6 to 11 years should receive Nucala as an injection administered by a healthcare professional; the pre-filled pen is intended for patients aged 12 and older. For EGPA, Nucala is approved for children aged 6 years and older. For CRSwNP, COPD, and HES, Nucala is not approved for use in patients under 18 years of age.
Pregnancy and Breastfeeding
There is limited clinical data on the use of Nucala during pregnancy. As a monoclonal antibody (IgG1), mepolizumab is expected to cross the placenta, particularly during the third trimester. As a precautionary measure, it is preferable to avoid use during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Nucala.
It is not known whether mepolizumab is excreted in human breast milk. Since immunoglobulins are generally present in breast milk, the possibility of exposure to the infant cannot be excluded. A decision should be made whether to discontinue breastfeeding or to discontinue Nucala therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Driving and Operating Machinery
Nucala has no or negligible influence on the ability to drive and use machines. The side effects known to occur with Nucala are unlikely to affect these abilities.
How Does Nucala Interact with Other Drugs?
Quick Answer: Nucala has a targeted mechanism of action and no formal drug-drug interaction studies have identified significant interactions with common medications. However, do not use Nucala concurrently with other anti-IL-5 biologics, and never abruptly stop existing controller medications.
Because mepolizumab is a monoclonal antibody that specifically targets IL-5, it is not metabolized by cytochrome P450 enzymes and is not expected to have pharmacokinetic interactions with conventional small-molecule drugs. No formal drug-drug interaction studies have been conducted. However, certain important considerations apply regarding concomitant medications:
| Medication / Class | Interaction Type | Clinical Recommendation |
|---|---|---|
| Oral Corticosteroids (e.g., prednisone, prednisolone) | Dose adjustment required | Do not abruptly stop. Nucala may allow gradual dose reduction under medical supervision. |
| Other anti-IL-5 biologics (e.g., benralizumab, reslizumab) | Duplicate mechanism – avoid | Concurrent use has not been studied and is not recommended due to overlapping mechanisms. |
| Other biologic asthma therapies (e.g., omalizumab, dupilumab, tezepelumab) | Potential immunomodulatory overlap | Switching between biologics may be appropriate; combining biologics is generally not recommended without specialist guidance. |
| Inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) | No interaction | Continue as prescribed. Nucala is an add-on treatment – do not stop ICS/LABA therapy. |
| Leukotriene receptor antagonists (e.g., montelukast) | No known interaction | Safe to continue alongside Nucala therapy. |
| Live vaccines | Theoretical concern | Consult your physician before receiving live or live-attenuated vaccines while on Nucala. Inactivated vaccines can be administered normally. |
| Anti-parasitic medications | Supportive consideration | Pre-existing parasitic infections should be treated before starting Nucala, as reduced eosinophils may impair parasite defense. |
Always inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter products, vitamins, and herbal supplements. Do not start or stop any medication without consulting your physician while on Nucala therapy.
What Is the Correct Dosage of Nucala?
Quick Answer: For severe eosinophilic asthma, CRSwNP, and COPD, the adult dose is 100 mg subcutaneously every 4 weeks. For EGPA and HES, the adult dose is 300 mg (three 100 mg injections) every 4 weeks. Children's dosing depends on age, weight, and condition.
Nucala is administered as a subcutaneous injection (under the skin). After appropriate training, patients or their caregivers may self-administer the injection at home using the pre-filled pen. For children aged 6 to 11, injections must be given by a healthcare professional. The following sections detail the recommended dosing by condition.
| Condition | Patient Group | Dose | Frequency |
|---|---|---|---|
| Severe Eosinophilic Asthma | Adults & adolescents ≥ 12 years | 100 mg (1 injection) | Every 4 weeks |
| Severe Eosinophilic Asthma | Children 6–11 years | 40 mg (dose by healthcare professional) | Every 4 weeks |
| CRSwNP | Adults (≥ 18 years) | 100 mg (1 injection) | Every 4 weeks |
| COPD | Adults (≥ 18 years) | 100 mg (1 injection) | Every 4 weeks |
| EGPA | Adults & adolescents ≥ 12 years | 300 mg (3 injections) | Every 4 weeks |
| EGPA | Children 6–11 years (≥ 40 kg) | 200 mg (2 injections) | Every 4 weeks |
| EGPA | Children 6–11 years (< 40 kg) | 100 mg (1 injection) | Every 4 weeks |
| HES | Adults (≥ 18 years) | 300 mg (3 injections) | Every 4 weeks |
When multiple injections are required to achieve the full dose (e.g., 300 mg for EGPA or HES), there must be at least 5 cm (2 inches) between each injection site. Preferred injection sites include the thigh and abdomen; if a caregiver is administering the injection, the upper arm may also be used.
Missed Dose
If you miss a scheduled dose, administer the injection as soon as you remember. If you do not realize the dose was missed until it is nearly time for the next scheduled injection, simply take the next dose as planned. Do not inject a double dose to make up for a missed one. If you are uncertain about what to do, consult your healthcare provider or pharmacist.
Overdose
If you believe you have injected more Nucala than prescribed, contact your healthcare provider for advice. In clinical studies, single doses of up to 700 mg intravenously have been administered without dose-limiting toxicity. There is no specific antidote for mepolizumab overdose; treatment would be supportive and symptomatic.
Stopping Treatment
Do not stop Nucala injections unless your doctor advises you to do so. Discontinuing treatment may cause your symptoms and exacerbations to return. If you experience worsening symptoms while receiving Nucala, contact your healthcare provider for assessment. Any decision to discontinue biologic therapy should be made in consultation with a specialist.
What Are the Side Effects of Nucala?
Quick Answer: The most common side effect is headache (very common, affecting more than 1 in 10 patients). Common side effects include injection site reactions, respiratory infections, urinary tract infections, pharyngitis, abdominal pain, back pain, and eczema. Serious allergic reactions including anaphylaxis are rare.
Like all medicines, Nucala can cause side effects, although not everybody gets them. Side effects are generally mild to moderate in severity but can occasionally be serious. The safety profile of mepolizumab has been extensively characterized in multiple Phase III clinical trials involving thousands of patients across all approved indications.
Allergic Reactions
Some patients may experience allergic or allergic-like reactions after receiving Nucala. These reactions can be common (affecting up to 1 in 10 people) and typically occur within minutes to hours after injection, though delayed reactions appearing several days later have also been reported. Symptoms may include chest tightness, cough, breathing difficulties, fainting, dizziness, swelling of the eyelids, face, lips, tongue or mouth, hives (urticaria), and skin rash.
If you experience signs of a severe allergic reaction (anaphylaxis) such as difficulty breathing, swelling of the face or throat, rapid heartbeat, dizziness, or collapse – seek emergency medical care immediately.
Side Effect Frequency
Very Common
- Headache
Common
- Lower respiratory tract infection (symptoms may include cough and fever)
- Urinary tract infection (blood in urine, painful and frequent urination, fever, lower back pain)
- Herpes zoster (shingles)
- Upper abdominal pain (stomachache or discomfort in the upper part of the abdomen)
- Fever (elevated body temperature)
- Eczema (itchy red patches on the skin)
- Injection site reaction (pain, redness, swelling, itching, and burning at the injection site)
- Back pain
- Arthralgia (joint pain)
- Pharyngitis (sore throat)
- Nasal congestion
Rare
- Anaphylaxis (severe, life-threatening allergic reaction)
If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Nucala?
Quick Answer: Store Nucala in a refrigerator (2–8°C). Do not freeze. Keep in the original packaging to protect from light. The pre-filled pen may be kept at room temperature (up to 30°C) for up to 7 days if needed.
Proper storage of Nucala is essential to maintain its effectiveness and safety. As a biologic medicine containing a monoclonal antibody protein, mepolizumab is sensitive to temperature extremes and light exposure. Improper storage can lead to protein denaturation, which may reduce the efficacy of the medication or increase the risk of adverse reactions.
- Refrigerator storage: Store at 2°C to 8°C (36°F to 46°F). This is the standard refrigerator temperature range.
- Do not freeze: Freezing can permanently damage the protein structure of mepolizumab. If the product has been frozen, it must be discarded.
- Protect from light: Keep the pre-filled pen in its original carton until ready for use.
- Room temperature storage: If necessary, the unopened pre-filled pen may be stored at room temperature (up to 30°C / 86°F) for a maximum of 7 days. If left out of the refrigerator for more than 7 days, it must be discarded.
- Before injection: Remove from refrigerator and allow to reach room temperature for 30 minutes before use. Do not use after more than 8 hours at room temperature outside the carton.
- Do not use after expiry date: Check the expiration date on the label and carton before each use. The expiry date refers to the last day of that month.
- Keep out of reach of children: Store Nucala where children cannot see or reach it.
Do not warm Nucala using a microwave, hot water, or direct sunlight. Do not shake the pen. Before use, inspect the solution through the inspection window – it should be clear (not cloudy), free from particles, and colorless to slightly yellow to slightly brown. One or more small air bubbles are normal and do not affect the injection.
What Does Nucala Contain?
Quick Answer: Each pre-filled pen contains 100 mg of mepolizumab in 1 mL solution. Inactive ingredients include sucrose, dibasic sodium phosphate heptahydrate, citric acid monohydrate, polysorbate 80, disodium edetate, and water for injections.
Nucala is supplied as a clear to opalescent, colorless to slightly yellow to slightly brown solution in a single-use pre-filled injection pen. Each pen delivers 1 mL of solution containing 100 mg of the active substance mepolizumab.
Active Substance
Mepolizumab (100 mg per pre-filled pen) – a humanized IgG1 kappa monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. Mepolizumab binds with high affinity to human interleukin-5 (IL-5), preventing IL-5 from binding to its receptor on the surface of eosinophils.
Inactive Ingredients (Excipients)
- Sucrose – acts as a stabilizer to maintain protein structure
- Dibasic sodium phosphate heptahydrate – buffering agent to maintain appropriate pH
- Citric acid monohydrate – buffering agent
- Polysorbate 80 (E 433) – surfactant to prevent protein aggregation (0.2 mg per 100 mg dose; may cause allergic reactions in sensitive individuals)
- Disodium edetate – chelating agent to prevent metal-catalyzed degradation
- Water for injections – solvent
Nucala contains less than 1 mmol (23 mg) sodium per 100 mg dose, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets.
Packaging
Nucala is available in packs containing 1 pre-filled pen, or in multipacks of 3 × 1 or 9 × 1 pre-filled pens. Not all pack sizes may be available in every country. The marketing authorization holder is GlaxoSmithKline Trading Services Limited, Dublin, Ireland.
Frequently Asked Questions About Nucala
Nucala (mepolizumab) is a biologic medicine used to treat several eosinophil-driven diseases. It is approved for severe eosinophilic asthma (as add-on maintenance treatment in patients aged 6+ years), chronic rhinosinusitis with nasal polyps (CRSwNP) in adults, eosinophilic granulomatosis with polyangiitis (EGPA) in patients aged 6+ years, chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype in adults, and hypereosinophilic syndrome (HES) in adults. It works by blocking interleukin-5 to reduce eosinophil levels in the body.
Nucala is given as a subcutaneous injection (under the skin) once every 4 weeks. After your healthcare provider determines that you or your caregiver can safely perform the injection and provides proper training, you may self-administer Nucala at home using the pre-filled pen. The pre-filled pen is designed for patients aged 12 years and older. Children aged 6 to 11 years must receive their injection from a healthcare professional. Suitable injection sites include the thigh and abdomen; a caregiver may also use the upper arm.
The most frequently reported side effect is headache, which is classified as very common (affecting more than 1 in 10 patients). Other common side effects include injection site reactions (pain, swelling, redness), lower respiratory tract infections, urinary tract infections, herpes zoster (shingles), pharyngitis (sore throat), back pain, joint pain, nasal congestion, upper abdominal pain, fever, and eczema. Serious allergic reactions including anaphylaxis are rare (up to 1 in 1,000). Most side effects are mild to moderate.
No, Nucala does not cure asthma. It is an add-on maintenance treatment that helps control severe eosinophilic asthma by reducing eosinophil-driven inflammation. Clinical trials have shown it can reduce exacerbations by approximately 50% or more and may allow significant reduction in oral corticosteroid doses. However, you should continue all your prescribed asthma controller medications (such as inhaled corticosteroids and long-acting bronchodilators) unless your doctor specifically instructs otherwise. The benefits of Nucala are maintained with ongoing treatment, and symptoms may return if therapy is discontinued.
There is limited clinical data on the use of Nucala during pregnancy. As a monoclonal antibody, mepolizumab is expected to cross the placenta, especially during the third trimester. It should be used during pregnancy only if the expected benefit justifies the potential risk. It is unknown whether mepolizumab passes into breast milk, though immunoglobulins are generally present in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare provider before starting or continuing Nucala therapy.
Nucala begins reducing blood eosinophil levels within the first few weeks of treatment. However, the full clinical benefit – such as reduced exacerbation rates and improved disease control – may take several months to become apparent. In clinical trials for severe asthma, benefits were typically observed within the first 4 to 12 weeks, with continued improvement over time. Healthcare providers generally recommend assessing treatment response after at least 4 to 6 months of therapy before making decisions about continuation.
References
This article is based on internationally recognized medical guidelines, regulatory documents, and peer-reviewed clinical trial data. All sources represent the highest level of medical evidence (Level 1A).
- European Medicines Agency (EMA). Nucala (mepolizumab) – Summary of Product Characteristics. Last updated 2026. Available at: EMA – Nucala EPAR
- U.S. Food and Drug Administration (FDA). Nucala (mepolizumab) Prescribing Information. GlaxoSmithKline, 2025.
- Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. The Lancet. 2012;380(9842):651-659.
- Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma (MENSA). New England Journal of Medicine. 2014;371(13):1198-1207.
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma (SIRIUS). New England Journal of Medicine. 2014;371(13):1189-1197.
- Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease (METREX/METREO). New England Journal of Medicine. 2017;377(17):1613-1629.
- Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. New England Journal of Medicine. 2017;376(20):1921-1932.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024. Available at: ginasthma.org
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD, 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising board-certified specialists in respiratory medicine, clinical pharmacology, and immunology. All medical content follows the GRADE evidence framework and adheres to international guidelines from the EMA, FDA, GINA, and WHO.
iMedic Medical Editorial Team – specialists in respiratory medicine and clinical pharmacology with documented academic background and clinical experience in biologic therapy management.
iMedic Medical Review Board – independent panel of medical experts who verify all content against current international guidelines, regulatory documents, and peer-reviewed clinical trial data.
All medical information on iMedic is based on evidence level 1A – the highest quality of evidence from systematic reviews and randomized controlled trials. We maintain strict editorial independence with no pharmaceutical company funding or sponsorship. Content is regularly reviewed and updated to reflect the latest clinical evidence and regulatory approvals. Read our full editorial standards.